Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia

Leukemia

Volumn 29, Issue 5, 2015, Pages 999-1003

  Cross, N C P ^a,b   White, H E ^a,b   Colomer, D ^c   Ehrencrona, H ^d   Foroni, L ^e   Gottardi, E ^f   Lange, T ^g   Lion, T ^h   Machova Polakova, K ⁱ   Dulucq, S ^j   Martinelli, G ^k   Oppliger Leibundgut, E ^l   Pallisgaard, N ^m   Barbany, G ⁿ   Sacha, T ^o   Talmaci, R ^p   Izzo, B ^q   Saglio, G ^f   Pane, F ^q,r   Muller M C ^s   Hochhaus, A ^t   more..

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^b SALISBURY DISTRICT HOSPITAL   (United Kingdom)

^c HOSPITAL CLÍNIC   (Spain)

^d LUND UNIVERSITY   (Sweden)

^e IMPERIAL COLLEGE LONDON   (United Kingdom)

^f UNIVERSITY OF TURIN   (Italy)

^g UNIVERSITY OF LEIPZIG   (Germany)

^h MEDICAL UNIVERSITY OF VIENNA   (Austria)

ⁱ INSTITUTE OF HEMATOLOGY AND BLOOD TRANSFUSION   (Czech Republic)

^j UNIVERSITÉ DE BORDEAUX   (France)

^k UNIVERSITY OF BOLOGNA   (Italy)

^l UNIVERSITY OF BERN   (Switzerland)

^m LILLEBAELT HOSPITAL   (Denmark)

ⁿ KAROLINSKA INSTITUTE   (Sweden)

^o JAGIELLONIAN UNIVERSITY   (Poland)

^p CAROL DAVILA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^q UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^r CEINGE BIOTECNOLOGIE AVANZATE   (Italy)

^s UNIVERSITY OF HEIDELBERG   (Germany)

^t JENA UNIVERSITY HOSPITAL   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN TYROSINE KINASE INHIBITOR; BCR ABL PROTEIN; BCR-ABL1 FUSION PROTEIN, HUMAN; PROTEIN TYROSINE KINASE;

ABL1 GENE; BCR GENE; CANCER PATIENT; CHRONIC MYELOID LEUKEMIA; GENE; GENE DOSAGE; GENE NUMBER; GUSB GENE; HUMAN; MOLECULAR GENETICS; MOLECULAR RESPONSE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; ANTAGONISTS AND INHIBITORS; CALIBRATION; EUROPE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETIC VARIATION; GENETICS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; LIMIT OF DETECTION; METABOLISM; POLYMERASE CHAIN REACTION; REPRODUCIBILITY; TREATMENT OUTCOME;

CALIBRATION; EUROPE; FUSION PROTEINS, BCR-ABL; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, LEUKEMIC; GENETIC VARIATION; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; LIMIT OF DETECTION; POLYMERASE CHAIN REACTION; PROTEIN-TYROSINE KINASES; REPRODUCIBILITY OF RESULTS; TREATMENT OUTCOME;

EID: 84929265404     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2015.29     Document Type: Review

References (34)

1. Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood 2013; 122: 872-884.
2. O'Brien S, Radich JP, Abboud CN, Akhtari M, Altman JK, Berman E et al. Chronic myelogenous leukemia, version 1.2015. 'J Natl Compr Canc Netw 2014; 12: 1590-1610.
3. Hughes T, Deininger M, Hochhaus A, Branford S, Radich J, Kaeda J et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood 2006; 108: 28-37.
4. Cross NC. Standardisation of molecular monitoring for chronic myeloid leukaemia. Best Pract Res Clin Haematol 2009; 22: 355-365.
5. Branford S, Cross NC, Hochhaus A, Radich J, Saglio G, Kaeda J et al. Rationale for the recommendations for harmonizing current methodology for detecting BCR-ABL transcripts in patients with chronic myeloid leukaemia. Leukemia 2006; 20: 1925-1930.
6. Branford S, Fletcher L, Cross NC, Muller MC, Hochhaus A, Kim DW et al. Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials. Blood 2008; 112: 3330-3338.
7. White HE, Matejtschuk P, Rigsby P, Gabert J, Lin F, Lynn Wang Y et al. Establishment of the first World Health Organization International Genetic Reference Panel for quantitation of BCR-ABL mRNA. Blood 2010; 116: e111-e117.
8. White HE, Hedges J, Bendit I, Branford S, Colomer D, Hochhaus A et al. Establishment and validation of analytical reference panels for the standardization of quantitative BCR-ABL1 measurements on the international scale. Clin Chem 2013; 59: 938-948.
9. Maute C, Nibourel O, Rea D, Coiteux V, Grardel N, Preudhomme C et al. Calibration of BCR-ABL1 mRNA quantification methods using genetic reference materials is a valid strategy to report results on the international scale. Clin Biochem 2014; 47: 1333-1336.
10. Hehlmann R, Grimwade D, Simonsson B, Apperley J, Baccarani M, Barbui T et al. The European LeukemiaNet: achievements and perspectives. Haematologica 2011; 96: 156-162.
11. Saglio G, Kim DW, Issaragrisil S, le Coutre P, Etienne G, Lobo C et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 2010; 362: 2251-2259.
12. Kantarjian H, Shah NP, Hochhaus A, Cortes J, Shah S, Ayala M et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2010; 362: 2260-2270.
13. Mahon FX, Rea D, Guilhot J, Guilhot F, Huguet F, Nicolini F et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol 2010; 11: 1029-1035.
14. Rousselot P, Charbonnier A, Cony-Makhoul P, Agape P, Nicolini FE, Varet B et al. Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease. J Clin Oncol 2014; 32: 424-430.
15. Cross NC, White HE, Muller MC, Saglio G, Hochhaus A. Standardized definitions of molecular response in chronic myeloid leukemia. Leukemia 2012; 26: 2172-2175.
16. Bustin SA, Benes V, Garson JA, Hellemans J, Huggett J, Kubista M et al. The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. Clin Chem 2009; 55: 611-622.
17. White H, Deprez L, Corbisier P, Hall V, Lin F, Mazoua S et al. A certified plasmid reference material for the standardisation of BCR-ABL1 mRNA quantification by eal time quantitative PCR. Leukemia 2014; 29: 369-376.
18. Gabert J, Beillard E, van der Velden VH, Bi W, Grimwade D, Pallisgaard N et al. Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe Against Cancer program. Leukemia 2003; 17: 2318-2357.
19. Branford S, Hughes T. Diagnosis and monitoring of chronic myeloid leukemia by qualitative and quantitative RT-PCR. Methods Mol Med 2006; 125: 69-92.
20. Jennings LJ, Smith FA, Halling KC, Persons DL, Kamel-Reid SMolecular Oncology Resource Committee of the College of American P. Design and analytic validation of BCR-ABL1 quantitative reverse transcription polymerase chain reaction assay for monitoring minimal residual disease. Arch Pathol Lab Med 2012; 136: 33-40.
21. Foroni L, Wilson G, Gerrard G, Mason J, Grimwade D, White HE et al. Guidelines for the measurement of BCR-ABL1 transcripts in chronic myeloid leukaemia. Br J Haematol 2011; 153: 179-190.
22. Beillard E, Pallisgaard N, van der Velden VH, Bi W, Dee R, van der Schoot E et al. Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using 'real-time' quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR) - a Europe against cancer program. Leukemia 2003; 17: 2474-2486.
23. Goldman JM, Gale RP. What does MRD in leukemia really mean? Leukemia 2014; 28: 1131.
24. nd edn. (EP17-A2) Clinical and Laboratory Standards Institute: Wayne, PA, USA, 2012.
25. Morley AA, Latham S, Brisco MJ, Sykes PJ, Sutton R, Hughes E et al. Sensitive and specific measurement of minimal residual disease in acute lymphoblastic leukemia. J Mol Diagn 2009; 11: 201-210.
26. Ladetto M, Lobetti-Bodoni C, Mantoan B, Ceccarelli M, Boccomini C, Genuardi E et al. Persistence of minimal residual disease in bone marrow predicts outcome in follicular lymphomas treated with a rituximab-intensive program. Blood 2013; 122: 3759-3766.
27. Morley AA. Digital PCR: a brief history. Biomol Detect Quantif 2014; 1: 1-2.
28. Goh HG, Lin M, Fukushima T, Saglio G, Kim D, Choi SY et al. Sensitive quantitation of minimal residual disease in chronic myeloid leukemia using nanofluidic digital polymerase chain reaction assay. Leuk Lymphoma 2011; 52: 896-904.
29. Jennings LJ, George D, Czech J, Yu M, Joseph L. Detection and quantification of BCR-ABL1 fusion transcripts by droplet digital PCR. J Mol Diagn 2014; 16: 174-179.
30. Bose S, Deininger M, Gora-Tybor J, Goldman JM, Melo JV. The presence of typical and atypical BCR-ABL fusion genes in leukocytes of normal individuals: biologic significance and implications for the assessment of minimal residual disease. Blood 1998; 92: 3362-3367.
31. Sobrinho-Simoes M, Wilczek V, Score J, Cross NC, Apperley JF, Melo JV. In search of the original leukemic clone in chronic myeloid leukemia patients in complete molecular remission after stem cell transplantation or imatinib. Blood 2010; 116: 1329-1335.
32. Ross DM, Branford S, Seymour JF, Schwarer AP, Arthur C, Bartley PA et al. Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR. Leukemia 2010; 24: 1719-1724.
33. Bartley PA, Ross DM, Latham S, Martin-Harris MH, Budgen B, Wilczek V et al. Sensitive detection and quantification of minimal residual disease in chronic myeloid leukaemia using nested quantitative PCR for BCR-ABL DNA. Int J Lab Hematol 2010; 32: e222-e228.
34. Hromadnikova I, Houbova B, Hridelova D, Voslarova S, Kofer J, Komrska V et al. Replicate real-time PCR testing of DNA in maternal plasma increases the sensitivity of non-invasive fetal sex determination. Prenat Diagn 2003; 23: 235-238.